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Summary The finding that human papillomavirus (HPV) genes can immortalise breast epithelial cells has led
to suggestions that HPV could be involved in the pathogenesis of breast cancer. Using the polymerase chain
reaction (PCR) we have been unable to demonstrate the presence of HPV DNA in a series of 80 breast
carcinomas.
Human papillomaviruses types 16 and 18 are commonly
associated with human cervical, anal and penile cancer (zur
Hausen, 1989 & Vousden, 1989), and the E6 and E7 proteins
encoded by these viruses can co-operate to immortalise
human genital keratinocytes in culture (Hawley-Nelson et al.,
1989; Munger et al., 1989 & Hudson et al., 1990). Breast
cancer is the commonest lethal malignancy affecting women
in the UK, but its aetiology and the underlying molecular
pathobiology are poorly understood. A recent report has
shown that human breast epithelial cells can also be im-
mortalised by HPV types 16 and 18 (Band et al., 1990),
although in this system expression of E6 alone was sufficient
(Band et al., 1991). These observations have raised the possi-
bility that HPV might be involved in the pathogenesis of
breast cancer. In view of this and the finding ofgenital HPVs
in malignancies at distant sites, such as the upper aero-
digestive tract (Syrjiinen, 1987) we have studied a large
number of breast cancer DNAs for the presence of genital
HPV types using the Polymerase Chain Reaction.
Materials and methods
DNA from 95 primary breast cancers, obtained at the time
of operation, was extracted as previously described (Luqmani
et al., 1989) by SDS lysis/proteinase-K digestion, phenol-
chloroform extraction and ethanol precipitation. Aliquots
were diluted to a concentration of 0.1 mg ml1 in TE
(10 mmol Tris, 1 mmol EDTA pH 7.5). Initial diagnosis was
by frozen section, confirmed subsequently by routine
examination of paraffin embedded tissue.
To demonstrate the presence of amplifiable DNA, 1 .g of
each test sample and six samples of serially diluted placental
DNA (2 fig, 1 yg, 100 ng, 10 ng, 1 ng, 100 pg) were amplified
with two primers, directed against a 109 basic pair fragment
of the P-globin gene, derived from those previously described
by Saiki et al. (1985, see Table I). Negative controls con-
tained ten to the ten molecules of HPV 18 DNA in pBR 322
or no DNA. Each reaction contained the test sample, 50 pmol
of each primer, 2.5 units of Taq DNA polymerase (Pro-
mega), 50 mM Potassium Chloride, 10 mM Tris, 1.5 mM
magnesium chloride, 0.1% Triton X-100 and 0.2 mM of each
of the nucleotides dATP, dCTP, dGTP, and dTTP at pH 8.8
all in a final volume of I00ILI. The reaction mix was covered
with 75 pl of light mineral oil and was subjected to 30 cycles
of 94°C 1 min, 37°C 1 min, 72°C 30 s. 12.5flI of the products
of the PCR reactions were electrophoretically analysed on a
1.5% agarose gel stained with ethidium.
The remaining satisfactory breast cancer DNAs were
amplified in type specific assays with primers directed against
sequences in the E7 open reading frames of HPV 16 and 18
(see Table I). Positive controls for this PCR consisted of 1 tLg
samples of placental DNA spiked with serial dilutions of
plasmids containing the relevant HPV type and cervical car-
cinoma DNAs known to be HPV positive. Reactions contain-
ing 1 pg of placental DNA or no DNA were used as negative
controls. The contents and volume of each reaction were as
given above and each was subjected to 30 cycles of 94°C
1 min, 55°C 1 min, and 72°C 30s. 12.5 fil of each product
was analysed electrophoretically on 1.5% agarose gels stained
with ethidium. These products were then transferred on to
nylon membranes by Southern blotting. The membranes pre-
hybridised at 50°C for 30 min in 5 x SSC, 2.5 x Denhardt's,
0.1% SDS, 0.1% sodium pyrophosphate and then hybridised
at the same temperature overnight to 32P-end labelled
oligonucleotide probes complementary to sequences of the
amplified products internal to the primers (see Table I). The
membranes were washed three times in 4 x SSC/0.1% SDS
for 5 min at room temperature and once in the same solution
for 20 min at 50°C.
Twenty of these DNAs were then analysed using consensus
PCR primers (GP 5,6) directed at the LI open reading of
genital HPVs using the conditions and thermal cycle profile
previously described (Snijders et al., 1990). This reaction has
been shown to detect genital HPV types 6b, 11, 13, 16, 18,
30, 31, 32, 33, 45 and 51 (van den Brule et al., 1990) and
theoretically could detect further as yet uncharacterised types
with homology in this part of the genome.
Results
The ,B-globin PCR could produce an observable band of the
correct size down to a dilution of 10 ng of genomic DNA per
reaction, as shown by the placental controls. This assay
demonstrated 15 of the original 95 DNA samples contained
inadequate material and were excluded from further analysis
(Figure 1). The details of the remaining 80 cases subsequently
tested for HPV are summarised in Table II. The type specific
HPV assays, were both sensitive to 10,000 copies of HPV
DNA per microgram of genomic DNA, which is equivalent
to one copy of HPV DNA per 15 diploid cells. No breast
cancer sample containing amplifiable DNA was positive for
HPV 16 or 18, while all positive and negative controls were
satisfactory (Figure 2). Using the consensus primers no HPV
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Table I Oligonucleotide primers and probes for PCR reactions
Oligonucleotide Primers for P-globin PCR;
5'-ACA CAA CTG TGT TCA CTA GCA-3'
5'-AAC TTC ATC CAC GTT CAC CTT-3'
gives a 109 base pair product
Oligonucleotide Primers for HPV 16 E7 PCR;
5'-TGG AGA TAC ACC TAC ATT GCA-3'
5'-ATT CCT AGT GTC CCC ATT AAC-3'
gives a 260 base pair product
Probe for HPV 16 PCR product;
5'-CAT TAC AAT ATT GTA ACC T1TT TGT
Oligonucleotide Primers for HPV 18 E7 PCR;
5'-ACC TTC TAT GTC ACG AGC AAT-3'
5'-TTC AGA AAC AGC TGC TGG AAT-3'
gives a 204 base pair product
bases; no. 567-587
no. 827-807
TGC AAG TGT G-3'
bases; no. 712-746
bases; no. 660-680
no. 864-844
Probe for HPV 18 PCR product;
5'-TCA GAG GAA GAA AAC GAT GAA ATA GAT GGA GT-3'
General Oligonucleotide Primers for Genital HPVs. bases; no. 689-720
5'-TTT GTT ACT GTG GTA GAT AC-3' GP 5
5'-GAA AAA TAA ACT GTA AAT CA-3' GP 6
gives a product of about 140 base pairs dependent on HPV types detected
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Figure 1 P-globin PCR. Lanes 1-6 Serial dilutions of placental DNA 1 jig-10 pg. Lanes 7-16 Breast carcinoma DNAs, No. 14
was excluded from the HPV PCR. Negative controls; lane 17, HPV 18 containing plasmid, lane 18, water.
Table II Clinical and histological details of the patients studied
Total number of tumours 80 Histological type
infiltrating ductal 58
Age range 29-76 infiltrating lobular 7
Mean age 54 other 7
not classified 8
Menopausal status
pre- 25 Oestrogen receptor status
post- 41 positive 42
peri- 5 negative 23
not known 9 not classified 15
was detected in any of the 20 DNAs tested and controls were
again satisfactory (data not shown).
extra-genital sites and that DNA from these viruses can
immortalise breast epithelial cells. However this study, using
a highly sensitive technique, shows that the HPV types most
commonly associated with ano-genital cancer are absent from
a large series of breast cancers. This does not preclude as yet
undiscovered HPV types or the very rare cancer associated
anogenital HPV types not detected by the consensus primers
playing a role in breast carcinogenesis, but a previous study
of 25 tumours analysed by low stringency. Southern blot also
failed to show any association between this group of viruses
and breast cancer (Ostrow et al., 1987). Although the in vitro
immortalisation of breast epithelial cells will provide an
excellent model in which to analyse HPV E6 function, the
present results refute any putative role for known oncogenic
genital HPVs in the pathogenesis of breast cancer.
Discussion
It has been shown that genital HPVs commonly associated
with cervical cancer can also be found in malignancies atABSENCE OF HPV IN BREAST CANCER 893
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Figure 2 HPV PCR; a and b. HPV 16, c and d. HPV 18, a and c. PCR products analysed on ethidium stained agarose gels. b and
d. Southern blots of the same gels probed with 32P-end labelled oligonucleotides internal to the PCR primers. Lanes 1-6, serial
dilutions (108 to 102) of relevant HPV plasmids in 1 jig of placental DNA. Lanes 7-16 Breast carcinoma DNAs. Lanes 17-19
controls, HPV + ye cervical carcinoma, placental DNA and water.
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